A new statement by the U.S. Food and Drug Administration (FDA) has required the addition of a boxed warning on oral lidocaine. Boxed warnings by the FDA are the most serious warning issued by the agency. In a release directly from the FDA, the public was warned against the use of prescription oral lidocaine 2 percent solutions in treating infant teething pain. It has been found that the prescription drug can cause severe harm and ...
Lidocaine Not Recommended for Treating Teething Pain
Posted January 9, 2015 in Product News and Recalls
FDA Issues Lidocaine Warnings
Posted July 18, 2014 in Product News and Recalls
The Food and Drug Administration (FDA) recently announced that manufacturers of oral viscous lidocaine will be required to have a “Boxed Warning,” which is the strongest level of warnings the FDA may require. The warning is specifically directed at use of lidocaine to relieve teething pain in children aged five months to three-and-a-half years old.
Many parents have been known to ...
continue reading...Lidocaine HCL Injection (1%) Recalled
Posted October 14, 2013 in Product News and Recalls | Recall
Recently, the U.S. Food and Drug Administration issued a news release warning the public of a voluntary nationwide recall of one lot of 1% Lidocaine HCL Injection. Hospira, Inc., the product manufacturer as well as the world’s largest provider of injectable drugs, has issued this recall due to the presence oxidized stainless steel found in the drug particulates.
According to the FDA, the specific product recalled is: 1% Lidocaine HCI Injection, USP, ...
continue reading...
